Table 1.
Endocrinological Data
| Case 1 | Case 2 | Normal Range | ||
|---|---|---|---|---|
| GH | (ng/mL) | 0.10 | 0.19 | |
| Peak GH | (ng/mL) | 7.8 | 16.1 | |
| ACTH | (pg/mL) | 4.3 | 13.7 | 7.7–63.1 |
| Peak ACTH | (pg/mL) | 5.3 | 22.8 | |
| Cortisol | (μg/dL) | 0.3 | 4.9 | |
| Peak cortisol | (μg/dL) | 0.3 | 5.7 | |
| TSH | (μIU/mL) | 1.9 | 1.6 | 0.4–4.9 |
| Peak TSH | (μIU/mL) | 4.6 | 6.6 | |
| PRL | (ng/mL) | 7.4 | 11.2 | 3.6–12.8 |
| Peak PRL | (ng/mL) | 70.9 | 150.8 | |
| LH | (μIU/mL) | 16.6 | 27.2 | 0.8–5.7 |
| FSH | (μIU/mL) | 6.9 | 53.3 | 0.7–1.5 |
| IGF-1 | (ng/mL) | 104.0 | 66.0 | |
| SD score | −0.9 | −1.9 | ||
| f-T4 | (ng/dL) | 1.0 | 1.2 | 0.7–1.5 |
| Testosterone | (ng/mL) | 5.9 | 5.4 | 2.9–9.5 |
| DHEA-S | (μg/dL) | NA | 166.0 | 240–2440 (age 61–70 y, male) |
| TPOAb | (IU/mL) | Negative | Negative | |
| TgAb | (ng/mL) | Negative | Negative | |
| TRAb | (IU/L) | Negative | Negative | |
| GADAb | (U/mL) | Negative | Negative | |
| IA-2Ab | (U/mL) | NA | Negative | |
| PAb | NA | Negative |
Provocative test for the evaluation of the pituitary function was performed by using insulin (0.025 unit/kg), TRH (200 μg). The hydrocortisone replacement therapy was performed before the provocative test and was discontinued 1 day before the test.
Abbreviations: DHEAS, dehydroepiandrosterone sulfate, GADAb, antiglutamic acid decarboxylase antibody; GH, growth hormone; IA2Ab, anti-insulinoma-associated protein-2 antibody; IGF-I, insulin-like growth factor-I; NA, not applicable; PAb, antipituitary cell antibody; PRL, prolactin; TgAb, antithyroglobulin antibody; TPOAb, antithyroid peroxidase antibody; TRAb, TSH receptor antibody.